Base editing correction of OCRL in Lowe syndrome: ABE-mediated functional rescue in patient-derived fibroblasts
Human Molecular Genetics · 2024
DOI: 10.1093/hmg/ddae045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2024. Verfasst von Siyu Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304, United States. Hauptthemen laut MEDLINE: Oculocerebrorenal Syndrome, Fibroblasts, Phosphoric Monoester Hydrolases, Genetic Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Children's Health Research Institute, Research to Prevent Blindness, Research for Prevention of Blindness Unrestricted.
Abstract (Originalsprache)
Lowe syndrome, a rare X-linked multisystem disorder presenting with major abnormalities in the eyes, kidneys, and central nervous system, is caused by mutations in OCRL gene (NG_008638.1). Encoding an inositol polyphosphate 5-phosphatase, OCRL catalyzes the hydrolysis of PI(4,5)P2 into PI4P. There are no effective targeted treatments for Lowe syndrome. Here, we demonstrate a novel gene therapy for Lowe syndrome in patient fibroblasts using an adenine base editor (ABE) that can efficiently correct pathogenic point mutations. We show that ABE8e-NG-based correction of a disease-causing mutation in a Lowe patient-derived fibroblast line containing R844X mutation in OCRL gene, restores OCRL expression at mRNA and protein levels. It also restores cellular abnormalities that are hallmarks of OCRL dysfunction, including defects in ciliogenesis, microtubule anchoring, α-actinin distribution, and F-actin network. The study indicates that ABE-mediated gene therapy is a feasible treatment for Lowe syndrome, laying the foundation for therapeutic application of ABE in the currently incurable disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304, United States.
- Department of Ophthalmology, Shanghai East Hospital, Tongji University School of Medicine, 150 Jimo Road, Pudong district, Shanghai 200120, China.
- Palo Alto Veterans Administration, 3801 Miranda Avenue, Palo Alto, CA 94304, United States.
ORCID-Profile: Siyu Chen
Förderung
- Children's Health Research Institute
- Research to Prevent Blindness
- Research for Prevention of Blindness Unrestricted
- International Retinal Research Foundation
- Bright Focus Foundation
- NEI NIH HHS
- Children’s Health Research Institute
- NIH
Zitieren
APA
Chen, S., Lo, C. H., Liu, Z., Wang, Q., Ning, K., Li, T., & Sun, Y. (2024). Base editing correction of OCRL in Lowe syndrome: ABE-mediated functional rescue in patient-derived fibroblasts. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddae045
Vancouver
Chen S, Lo CH, Liu Z, Wang Q, Ning K, Li T, et al. Base editing correction of OCRL in Lowe syndrome: ABE-mediated functional rescue in patient-derived fibroblasts. Human Molecular Genetics. 2024. doi:10.1093/hmg/ddae045
BibTeX
@article{Chen2024,
author = {Chen, Siyu and Lo, Chien-Hui and Liu, Zhiquan and Wang, Qing and Ning, Ke and Li, Tingting and Sun, Yang},
title = {Base editing correction of OCRL in Lowe syndrome: ABE-mediated functional rescue in patient-derived fibroblasts},
journal = {Human Molecular Genetics},
year = {2024},
doi = {10.1093/hmg/ddae045}
}
EUVIMED